A Phase 1 interventional study of MediNF and ShamMediNF in Depression - Major Depressive Disorder and Depression Disorders, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of California, San Diego · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depression by University of California, San Diego — 6 open to participants now, 10 under way, 1 of them phase 3. Depression · University of California, San Diego.
Among the 30 studies in Depression by University of California, San Diego, this one is the 17th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2024, is the only one in phase 1, and was the 27th registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →6 of the 30 studies in Depression by University of California, San Diego are open now, in 1 country. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 18–65
University of California, San Diego · Sites in United States
Ages 45–75 · Women only
University of California, San Diego · Sites in United States
Ages 21–55
University of California, San Diego · Sites in United States
Ages 18–65
University of California, San Diego · Sites in United States
Ages 13–17 · Healthy volunteers
By country, each count listing its studies:
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 1
First in 2006; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 81 across 7,066 interventional studies indexed under Depression.
Median enrollment 73 across the 27 interventional studies, 248 across the 3 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Diego is the lead sponsor of 980 studies on the registry; 195 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
4 of the studies in Depression by University of California, San Diego that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT06269146University of California, San DiegoPramipexole to Enhance Social Connections | 2026-11 |
| NCT05682677University of California, San DiegoCombined Neuromodulation and Cognitive Training for Post-mTBI Depression | 2027-06-30 |
| NCT06675240University of California, San DiegoMeditative Neurofeedback for Depression | 2027-11-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Depression by University of California, San Diego, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to test a meditative neurofeedback intervention for depressed mood.
The goal of this study is to test whether a 5-session meditative neurofeedback intervention significantly alleviates depressive symptoms as well as improves secondary outcomes of rumination and mindfulness.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
This study's planned enrollment of 60 is below the median of 81 across 7,066 interventional studies indexed under Depression.
Browse Depression studies →University of California, San Diego is the lead sponsor of 980 studies on the registry; 195 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
Behavioral: MediNF
Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided that is yoked to a closely-matched individual in the experimental arm.
Behavioral: ShamMediNF
No contact during the 4 week intervention period
Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided that is yoked to a closely-matched individual in the experimental arm.
Change in FCz-FC4 alpha band coherence (iCoh)
EEG alpha band (8-12 Hz) imaginary coherence between FC4 and FCz electrodes is the primary outcome, higher scores represent better outcome, and the coherence measure is unitless.
Time frame: 8 weeks
Change in EEG source localized right ACC - Insula alpha band connectivity
EEG source-localized right Anterior Cingulate Cortex (ACC) - Insula alpha band (8-12 Hz) connectivity during an attention to breathing task will serve as a secondary neural outcome, higher scores represent better outcome. The measure is based on regional neural activity correlations and is unitless.
Time frame: 8 weeks
PHQ9
Self-rated depression symptoms on the Patient Health Questionnaire 9 item scale (PHJQ9), min 0 max 27 with lower scores representing better outcome.
Time frame: 8 weeks
MADRS
Clinician rated depression symptoms on the Montgomery Åsberg Depression Rating Scale (MADRS), min 0 max 54 with lower scores representing better outcome.
Time frame: 8 weeks
GAD7
Anxiety symptoms on the Generalized Anxiety Disorder 7-item (GAD7) scale, min 0 max 21 with lower scores representing better outcome.
Time frame: 8 weeks
RRS
Rumination on the Ruminative Response Scale (RRS), min 22 max 88 with lower scores representing better outcome
Time frame: 8 weeks
MAAS
Mindfulness on the Mindful Attention Awareness Scale (MAAS), min 6 max 84 with higher scores representing better outcome.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.
Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 36 months is close to that.
Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Diego →